NPM1 and acute myeloid leukemia: There was no significant heterogeneity in AML risk when cases and controls were stratified by either NPM1 or FLT3 mutation status, although there was a trend towards higher risk for NPM1-mutated AML (OR 1.96, 95% CI 1.29–2.98; P = 1.7 × 10−3) and FLT3-mutated AML (OR 1.52, 95% CI 1.07–2.16; P = 0.02) compared to NPM1-wildtype AML (OR 1.28, 95% CI 0.97 –1.68; P = 0.08) or FLT3-wildtpe AML (OR 1.26, 95% CI 1.01–1.58; P = 0.04) (Supplementary Table 6).